Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC).
Niederwieser C, Iacobelli S, Franke GN, Koster L, van Os M, Platzbecker U, Hübel K, Scheid C, Müller LP, Stelljes M, Morozova E, Passweg J, Onida F, Dreger P, Saccardi R, Ladetto M, Salmenniemi U, Bethge W, Poiré X, Kobbe G, McLornan DP, Robin M, Kröger N.
Niederwieser C, et al. Among authors: kroger n.
Bone Marrow Transplant. 2024 Apr 25. doi: 10.1038/s41409-024-02282-7. Online ahead of print.
Bone Marrow Transplant. 2024.
PMID: 38664589